7 results about "Viral rna" patented technology

This invention belongs to the field of biomedical technology, specifically disclosing a scorpion-derived polypeptide for combating influenza virus and its applications. The scorpion-derived polypeptide has the amino acid sequence shown in SEQ ID NO:1, or is a functional variant obtained by substitution, deletion, and / or addition of one or more amino acids from the same sequence, retaining its anti-influenza virus activity. The scorpion-derived polypeptide provided by this invention can significantly inhibit the proliferation of influenza A virus and substantially reduce the expression levels of viral RNA and protein within a non-cytotoxic concentration range. It also effectively reduces viral load and inflammatory factor levels in mice infected with influenza A virus, exhibiting excellent anti-influenza A virus activity and being less likely to induce viral resistance. This invention provides a novel, highly efficient, and low-toxicity bioactive molecule for influenza prevention and control, which can be applied to the development of anti-influenza drugs.

This invention discloses the application of bufotoxin lactones in the preparation of anti-IHNV products, belonging to the field of biomedical technology. This invention is the first to discover and confirm that four bufotalin-based drugs (bufotalin, bufotalin ester, bufotalin, and bufotalin) have significant anti-IHNV effects: their IC50 values ​​against IHNV in vitro range from 0.0879 to 0.1809 μM, with selectivity indices all greater than 110. After 48 hours of treatment, they can reduce viral RNA expression by 110 to 173 times and viral titer by 4.36 to 5.15 lg; they also show broad-spectrum inhibitory effects against different genotypes of IHNV, such as LN-15, QH-17, and Blk94; in a rainbow trout in vivo model, after administration of a 0.5 mg / kg dose, the cumulative mortality rate decreased from 95% in the control group to 13.3% to 21.7%, with the highest relative protection rate reaching 85.96% (bufotalin), indicating that these compounds have highly efficient, broad-spectrum, and low-toxicity anti-IHNV activity and have excellent application prospects.

This invention belongs to the fields of bioinformatics and protein function identification, specifically relating to a machine learning-based method for identifying viral RNA silencing repressors. The method includes: obtaining the amino acid sequence of the viral protein to be tested, inputting it into a pre-trained ESM-2 model to extract deep feature vectors, then inputting the feature vectors into a trained XGBoost classifier, and outputting an identification result indicating whether the viral protein is a viral RNA silencing repressor. This invention integrates the automatic feature extraction capability of ESM-2 with the efficient classification performance of XGBoost, significantly improving prediction accuracy and generalization ability. It is mainly used in fields such as plant antiviral genetic engineering, disease-resistant breeding, and biopesticide development, enabling rapid screening of potential viral RNA silencing repressors and providing an efficient tool for functional gene mining.

Provided herein are methods of inhibiting a respiratory virus (i.e., a virus associated with a respiratory condition, such as influenza A virus, influenza B virus, RSV, etc.). Aspects of the methods include contacting a sample comprising viral RNA (vRNA) having a target motif with an effective amount of an agent that specifically binds the target motif to inhibit the respiratory virus. Also provided are methods of treating or preventing a respiratory virus infection in a subject. Also provided are compounds and pharmaceutical compositions comprising an oligonucleotide sequence complementary to a target vRNA region, which can be used in the subject methods. The provided oligonucleotides can comprise 5-methylcytosine.

The present invention relates notably to specific single-domain antibodies (sdAbs) targeting RNA-dependent RNA polymerase (RdRp) activity and their use in the prevention and / or treatment of a virus infection from Coronaviruses, and more particularly of SARS-CoV-2.

This invention belongs to the field of molecular biology, specifically relating to the application of SND1-overexpressing cells in promoting small RNA virus replication. The invention first constructs an SND1 gene overexpression vector, transfects it into BHK-21 cells, and then selects a stable cell line. Infection of the cell line with foot-and-mouth disease virus (FMDV) and Seneca virus (SVV) revealed that the titers of FMDV and SVV, as well as the expression levels of viral RNA and proteins, were significantly higher than in wild-type cells, indicating that SND1 promotes FMDV and SVV replication. The constructed SND1-overexpressing cells can efficiently proliferate FMDV and SVV and can be used as cell lines for FMDV and Seneca virus vaccine production. This provides a new tool for FMDV and SVV mechanism research, vaccine preparation, and the development of detection reagents, and has significant scientific research and application value.

Positive reference spiked in collected sample for use in qualitatively and quantitatively detecting viral RNA.